Board of Directors

The board of Ascelia Pharma consists of:

Peter Benson
Peter Benson

Born 1955. Chairman of the board of directors since 2017.

Professional background
Peter Benson is co-founder and Managing Partner of Sunstone Capital Life Science Ventures and chairman of Alligator Bioscience AB, which is listed on Nasdaq Stockholm. Peter Benson has extensive experience from the Life Science sector as an investor, board member and in management positions, including in several listed companies. Peter Benson was vice chairman of Zealand Pharma during its IPO and has previously inter alia been Head of Life Science Ventures at Vækstfonden (the Danish Growth Fund), President of Hospital Care and Senior Vice President at Pharmacia as well as Vice President Marketing & Sales at Kabi Pharmacia Parenterals.
Education
Graduate in business administration from Lund University, Sweden. MA in Economics from the University of California, US.
Other ongoing assignments
Chairman of Alligator Bioscience AB (publ), Ascelia Incentive AB, Good Partners Media Group AB and Sunstone LSV Partners Holding ApS. Board member of Adenium Biotech ApS, Arcoma Aktiebolag, CMC SPV of 3 April 2017 AB, Jollingham AB, Montela Aktiebolag, Opsona Therapeutics Ltd. and Sunstone Capital A/S (and subsidiaries within the Sunstone Capital A/S sphere). Deputy board member of JellyBean Aktiebolag.
Holdings in Ascelia
-
Independence
Independent in relation to the Company and its management, but not in relation to major shareholders. Managing Partner of Sunstone Life Science Venture A/S and board member of CMC SPV of 3 April 2017 AB.
Bo Jesper Hansen
Bo Jesper Hansen

Born 1958. Member of the board of directors since 2010.

Professional background
Bo Jesper Hansen has extensive experience from orphan drug research and development, international marketing and business development. Bo Jesper Hansen is and has previously been chairman and member of the board of directors in a number of biotech and pharma companies, including executive chairman of Swedish Orphan Biovitrum AB (publ), Topotarget A/S (publ) and Karolinska Development AB (publ) and chairman of Ablynx nv (publ).
Education
M.D. and Ph.D. from University of Copenhagen, Denmark.
Other ongoing assignments
Chairman of Innoventa Medica ApS and Laborie Inc. Board member of Azanta A/S. Vice-chairman of Orphazyme ApS.
Holdings in Ascelia
216,164 shares in Ascelia Pharma AB. Bo Jesper Hansen also holds approximately 4 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB.
Independence
Independent in relation to the Company and its management, but not in relation to major shareholders. Shareholder in CMC SPV of 3 April 2017 AB.
Hans Maier
Hans Maier

Born 1955. Member of the board of directors since 2017.

Professional background
Hans Maier has held senior positions within Schering AG and Bayer AG in Europe and Asia, inter alia as Managing Director in Korea and in Japan, Head of Corporate Strategy and Business Development of Schering AG and Head of the Global Business Unit Diagnostic Imaging in both Schering AG and Bayer AG. Hans Maier is member of several advisory boards, inter alia the Fraunhofer Institute for Medical Image Computing and the German Heart Center Berlin. Hans Maier is a member of several supervisory and advisory boards, including the German Heart Center Berlin (President of the Board of Trustees) and the Fraunhofer Mevis Institute for Medical Image Computing (Chairman of the Advisory Board).
Education
Ph.D. in Economics and Social Sciences and Degree in Political Science from Freie Universität Berlin, Germany.
Other ongoing assignments
Board member of Deutsches Herzzentrum Berlin and Fraunhofer Institute for Medical Image Computing MEVIS. Co-Founder and Managing Partner of BGM Associates GmbH.
Holdings in Ascelia
10,000 shares in Ascelia Pharma AB.
Independence
Independent in relation to the Company and its management, and in relation to major shareholders.
Niels Mengel
Niels Mengel

Born 1948. Member of the board of directors since 2000.

Professional background
Niels Mengel is Founding Partner, board member and CEO of Øresund-Healthcare Capital. Niels Mengel has extensive experience from the healthcare industry as an investor. Niels Mengel has previously inter alia been Executive Vice President at ISS World Services A/S and Director at PA Consulting Group.
Education
M.B.A. from London Business School, England. M.Sc. in Macro Economy and Finance from University of Copenhagen, Denmark.
Other ongoing assignments
Chairman of Dansk Aktionærforening. Board member of Better Finance (The European Federation of Investors and Financial Services Users), Black Swan Strategy A/S and Upstream Invest A/S. Board member and managing partner of Øresund-Healthcare Management A/S. Limited partner of Øresund-Healthcare Capital K/S. Partner of ØHM Exit I I/S and ØHM Exit II I/S. Member of management (executive) in Kibegeon ApS.
Holdings in Ascelia
Niels Mengel, has directly and indirectly, invested in Øresund-Healthcare Capital K/S that holds (i) 2,020,459 shares in Ascelia Pharma AB and (ii) approximately 5 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB. Through the agreements governing Niels Mengel’s investments in Øresund-Healthcare Capital K/S, Niels Mengel has a financial interest corresponding to (a) approximately 50 per cent of the shares in Ascelia Pharma AB held by Øresund-Healthcare Capital K/S and (b) 100 per cent of the shares in CMC SPV of 3 April 2017 AB held by Øresund-Healthcare Capital K/S.
Independence
Independent in relation to the Company and its management, but not in relation to major shareholders. Founding partner of Øresund-Healthcare Capital K/S.
René Spogárd
René Spogárd

Born 1954. Member of the board of directors since 2017.

Professional background
René Spogárd is chairman and investor in a number of companies including JEKA Fish A/S, Bollerup Jensen A/S and Flex Funding A/S. René Spogárd has extensive experience from investing in the healthcare sector and board positions in a public environment. René Spogárd has previously inter alia been owner and Managing Director at TNS Gallup A/S and Director at TNS plc (listed on London Stock Exchange).
Education
H.D. in Marketing from Copenhagen Business School, Denmark.
Other ongoing assignments
Chairman of Ambrox Property Invest III A/S, Bollerup Jensen A/S, Bollerup Jensen Adhesives ApS, Bollerup Jensen Water Holding ApS, CMC SPV of 3 April 2017 AB, Cimbric A/S, Deltaq Portefølje Holding 104 ApS, Deltaq Portefølje Holding II ApS, Deltaq Portefølje Holding IV ApS, Deltaq Portefølje Holding VI ApS, Flex Funding A/S, Jeka Fish A/S, Jeka Fish Holding ApS, Jeka Fish Holding 2 ApS, Jysk Industri Holding A/S and Preservation Technologies I/S. Deputy chairman of Nordisk Krabbe Kompagni A/S. Board member of Ambrox Capital A/S, Ambrox Korsør A/S, Bollerup Jensen Adhesives Holding ApS, Bollerup Jensen Water ApS, Bollerup Jensen Wood ApS and Flex Funding Fintech ApS. Member of management (executive) and partner of Dadephi ApS, René Spogárds amilieanpartsselskab, Spogárd Holding ApS, Spogárd Invest ApS and Spogárd Invest 3 ApS.
Holdings in Ascelia
333,418 shares in Ascelia Pharma AB indirectly through company. René Spogárd also indirectly holds approximately 24 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB.
Independence
Independent in relation to the Company and its management, but not in relation to major shareholders. Shareholder in and chairman of the board of directors of CMC SPV of 3 April 2017 AB.
Helena Wennerström
Helena Wennerström

Born 1965. Member of the board of directors since 2017.

Professional background
Helena Wennerström has been Executive Vice President of Bulten AB (publ) since 2014 and has been its Chief Financial Officer since 2006. Helena Wennerström's work within Bulten AB also includes the Investor Relations and Communications activities and IT. Helena Wennerström has earlier served finance roles at Digitalfabriken and Topcon.
Education
Master of Science in Business Administration and Economics from Örebro University.
Other ongoing assignments
Chairman of Bulten Fasteners AB. Board member of Bulten Hallstahammar AB, Bulten North America LLC, Bulten Polska S.A., Bulten Sweden AB, Bulten Fasteners (China) Co Ltd. and BBB Services Ltd. Deputy board member of Bulten Industrifastighet AB, Finnveden Micro Fasteners AB and Finnveden Trading Aktiebolag. Deputy Managing Director of Bulten AB.
Holdings in Ascelia
8,000 shares in Ascelia Pharma AB.
Independence
Independent in relation to the Company and its management, and in relation to major shareholders.

Mangoral

Our lead candidate Mangoral is a liver imaging drug (i.e. a liver specific contrast agent) being developed for detection and localization of potential liver metastases, using Magnetic Resonance Imaging (“MRI”) in patients where use of the current gold standard gadolinium-based contrast agents (“GBCAs”) may be medically inadvisable or cannot be administered. Mangoral is currently ready for Phase III clinical development.

Oncoral

Oncoral is a novel tablet-based formulation of the well-known chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric (stomach) cancer. Irinotecan is today mainly used for treating metastasized colorectal cancer. Although irinotecan is currently not approved for treating gastric cancer in the United States and in the EU, there is off-label use for this indication. Oncoral is currently being evaluated in an investigator sponsored Phase I study.

DEVELOPMENT PLAN

Ascelia has established a development program for lead candidate Mangoral, consisting of a pivotal Phase III efficacy study and two supportive studies. The clinical development strategy for Oncoral, Ascelia´s second drug candidate, is to obtain Phase II data and then to partner for the further development.